The new corona virus SARS-CoV-2 has been raging since January 2020, spreading at an unprecedented pace, exhibiting insidious properties and puzzling experts. SCHURTER has taken this fact into account and has ramped up the production of its medical products.
Thanks to decades of expertise in manufacturing as a supplier of medical technology, SCHURTER was able to avert the lockdown of many of its production facilities. Pandemic and system-relevant plants were closed in very few countries.
SCHURTER took advantage of this situation and decided to drastically increase its capacities in favour of the production of components and input systems for medical technology.
Collaboration aims to accelerate Europe’s adoption of chiplets and advanced 2.5D and 3D chip packaging…
NVIDIA will continue to distribute SchedMD’s open-source, vendor-neutral Slurm software, ensuring wide availability for high-performance…
Powered by Stratasys (NASDAQ: SSYS) technology, Airbus is producing more than 25,000 flight-ready 3D-printed parts…
Funding will support Quantum Art in reaching a 1,000-qubit commercial platform and global expansion Quantum…
Hud automatically captures live service and function-level data from production- providing the missing context for…
General Atlantic leads round valuing company at $800M as Port tackles the 90% of developer…
